Everolimus benefited bladder cancer patient with rare genetic mutations Healio Genomic profiling of the tumor of an “exceptional responder” with advanced bladder cancer revealed two mutations that may have been responsible for the patient's 14-month complete response to combined treatment with everolimus and pazopanib. |
